证券代码：688217 证券简称：睿昂基因 公告编号：2025-052 上海睿昂基因科技股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 14 日 本次会议由公司董事会召集，董事长高尚先先生主持，以现场投票与网络投 票相结合的方式表决。会议的召集、召开及表决程序符合《中华人民共和国公司 法》《上海证券交易所科创板股票上市规则》《上海睿昂基因科技股份有限公司章 程》等有关法律、行政法规、部门规章、规范性文件以及公司管理制度的有关规 定。 （五） 公司董事和董事会秘书的出席情况 1、 公司在任董事8人，出席8人； 2、 副总经理兼董事会秘书周海红女士出席本次会议，副总经理张成俐女士、副 总经理谢立群女士、财务总监王春娟女士列席本次会议。 （二） 股东会召开的地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会议 室 （三） 出席会议的普通股股东、特别表 ...

Market Overview - The precision medicine sector experienced a slight decline of 0.01% on November 12, with Guomai Technology leading the drop [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance - Zhongyuan Xiehe saw a significant increase of 10.00%, closing at 28.61 with a trading volume of 311,400 shares and a transaction value of 857 million [1] - Yangpu Medical and Beilu Pharmaceutical also reported gains of 4.13% and 2.96%, respectively [1] - Guomai Technology, on the other hand, declined by 3.17%, closing at 11.62 [2] Capital Flow - The precision medicine sector saw a net inflow of 311 million from institutional investors, while retail investors experienced a net outflow of 318 million [2] - Major stocks like Zhongyuan Xiehe and Yaoming Kangde attracted significant institutional investment, with net inflows of 1.941 billion and 76.27 million, respectively [3] Individual Stock Highlights - Zhongyuan Xiehe had a net institutional inflow of 1.941 billion, accounting for 22.65% of its trading volume, while retail investors withdrew 932 million [3] - Yaoming Kangde also saw a net institutional inflow of 76.27 million, with retail investors withdrawing 430 million [3] - Other notable stocks with positive institutional inflows include Beilu Pharmaceutical and Yangpu Medical, with net inflows of 33.03 million and 26.56 million, respectively [3]

上海睿昂基因科技股份有限公司 2025 年第四次临时股东会会议资料 证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司 2025 年第四次临时股东会 会议资料 2025 年 11 月 | 议案一《关于续聘会计师事务所的议案》 7 | | --- | 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照/注册证书复印件 （加盖公章）、授权委托书等，上述登记材料均需提供复印件一份，个人登记材 料复印件须个人签字，法定代表人证明文件复印件须加盖公司公章，经验证后方 可出席会议。会议开始后,由会议主持人宣布现场出席会议的股东人数及其所持 有表决权的股份总数，在此之后进场的股东无权参与现场投票表决。 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人依法享有发言权、质询权、表决权等权利。股东及股 东代理人参加股东会应认真履行其法定义务，不得侵犯公司和其他股东及股东代 理人的合法权益，不得扰乱股东会的正常秩序。 五、要求发言的股东及股东代理人，应当按照会议的议程，经会议主持人许 可方可发言。有多名股东及股东代理人 ...

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Core Points - The company has announced the appointment of Zhonghui Certified Public Accountants as its auditing firm for the fiscal year 2025, pending approval from the shareholders' meeting [10][21][22] - The company plans to hold its fourth extraordinary shareholders' meeting on November 14, 2025, to discuss the appointment of the auditing firm and other matters [24][25] - The company reported a provision for asset impairment totaling 3,244,068.70 yuan for the third quarter of 2025, which includes credit impairment losses and inventory write-downs [36][40] Financial Data - The company intends to recognize credit impairment losses of 3,146,208.22 yuan for accounts receivable and other receivables [38] - An additional inventory write-down of 97,860.48 yuan has been proposed due to the cost of inventory exceeding its net realizable value [39] - The total impact of the impairment provisions on the company's profit for the third quarter of 2025 is expected to be a reduction of 3,244,068.70 yuan [40] Shareholder Information - The company has confirmed that the total number of shareholders and the status of major shareholders will be disclosed in the upcoming shareholders' meeting [5][6] - The company has a repurchase account holding 669,621 shares, representing 1.20% of the total share capital [6] Audit Firm Information - Zhonghui Certified Public Accountants has been in operation since December 2013 and has a significant number of registered accountants and partners [12][14] - The firm has not faced any civil liability in the past three years related to its auditing practices [14] - The audit fee for the company in 2025 is set at 1 million yuan, consistent with the previous year's fee [19]

Group 1 - The treatment level for lymphoma, particularly Diffuse Large B-cell Lymphoma (DLBCL), has significantly improved over the past 20 years, with a 5-year overall survival rate exceeding 60% [1] - Despite advancements, a considerable number of newly diagnosed DLBCL patients do not achieve complete remission after standard treatment (R-CHOP regimen) and face a high risk of relapse [1] - The development of precision-targeted therapies has diversified treatment options, leading to improved outcomes for previously poorly responding DLBCL patients [1] Group 2 - Traditional efficacy assessment for lymphoma relies on PET-CT imaging, which has limitations such as increased radiation dose and difficulty in distinguishing between active immune cells and tumor lesions [2] - PET-CT assessments are typically conducted only after three and six treatment cycles, hindering early detection of treatment failures [2] - Liquid biopsy technology based on circulating tumor DNA (ctDNA) is being explored for its clinical application, as ctDNA can serve as a molecular marker for tumor burden and treatment response [2] Group 3 - Shanghai Ruian Gene Technology Co., Ltd. has developed a "B-cell lymphoma ctDNA detection kit" with patented probes and algorithms, showing promising research results in collaboration with Ruijin Hospital [3] - The kit allows for the assessment of DLBCL patients' responses to standard treatment after just one treatment cycle, and pre-treatment ctDNA detection can predict early chemotherapy failure [3] - The successful development of this detection kit is expected to advance clinical trials and enhance precision diagnosis and treatment for lymphoma patients in China once approved by the National Medical Products Administration (NMPA) [3]

Core Viewpoint - Ruiang Gene (688217.SH) reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters of 2025 was 139 million yuan, representing a year-on-year decrease of 26.64% [1] - The net profit attributable to shareholders of the parent company was -5.62 million yuan, compared to a net profit of 5.73 million yuan in the same period last year [1] - The basic earnings per share were -0.1 yuan [1]

根据《企业会计准则》以及上海睿昂基因科技股份有限公司（以下简称"公 司"）会计政策、会计估计的相关规定，为了真实、准确地反映公司 2025 年第 三季度的财务状况和经营成果，本着谨慎性原则，对 2025 年 7 月 1 日至 2025 年9月30日公司及子公司相关信用及资产进行了减值测试并计提了相应的减值 准备。2025 年第三季度公司拟计提各类信用及资产减值准备共计 3,244,068.70 元。具体情况如下： 证券代码：688217 证券简称：睿昂基因 公告编号：2025-051 上海睿昂基因科技股份有限公司 关于 2025 年第三季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提减值准备情况概述 三、计提减值准备对公司的影响 2025 年第三季度公司合并报表口径计提各类信用减值损失、资产减值损失 减值准备合计 3,244,068.70 元，减少公司 2025 年第三季度利润总额影响数 3,244,068.70 元（合并利润总额未计算所得税影响）。 公司 2025 年第三季度计提资产减 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2025-049 上海睿昂基因科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事成员保证公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、拟聘任会计师事务所的基本情况 组织形式：特殊普通合伙 注册地址：杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室 （一）机构信息 1、基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服 务业务。 事务所名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 首席合伙人：高峰 上年度末（2024 年 12 月 31 日）合伙人数量：116 人 上年度末（2024 年 12 月 31 日）注册会计师人数：694 人 上年度末（2024 年 12 月 31 日）签署过证券服务业务审计报告的注册会计 拟聘任的会计师事务所名称：中汇会计师事务所（特殊普通合伙）（以 下简称"中汇会计师事务所" ...

一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第四次临时股东会 召开日期时间：2025 年 11 月 14 日 14 点 30 分 证券代码：688217 证券简称：睿昂基因 公告编号：2025-050 上海睿昂基因科技股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 召开地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 14 日 至2025 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：2025年11月14日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次 ...